NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine whether Doxycycline can be used to control
nosebleeds (epistaxis) for patients with Hereditary Hemorrhagic Telangiectasia (HHT).
Patients with HHT will be randomized to one of 2 study arms: Doxycycline or Placebo for a
period of 2 months followed by a 1-month washout period before switching treatments for a
further 2 months period. Observation and evaluation will continue for a period of one month
after treatment is completed.